New updates have been reported about Resilience Care.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Resilience Care has formally launched its digital oncology platform in the U.S., aiming to close the “between-visit” gap in cancer care that often leaves clinicians unaware of evolving toxicities at home. Already deployed as a standard of care in more than 200 centers and used by over 35,000 patients across Europe, the company will now target American oncology providers with its remote symptom-monitoring and triage solution.
To drive this expansion, Resilience Care has named former Jasper Health executive Greg Orr as U.S. General Manager, leveraging his experience in scaling cancer navigation platforms and building strategic partnerships. The company has also assembled a U.S. advisory board featuring digital health and oncology leaders, including U.S. president Eddie Martucci, industry advisor Jill DeSimone, and chief nursing advisor Anne Ireland, to guide market entry, commercialization, and clinical integration.
Resilience Care’s platform provides continuous symptom tracking, personalized digital support, and adaptive care pathways, allowing routine, low-grade issues to be managed through automated education and digital programs. This model is designed to free nursing capacity by filtering non-critical communication and highlighting early risk signals, with European data indicating a 4–5x increase in nursing productivity and an 85% patient adherence rate after one year of use.
The system gives oncology teams real-time, structured patient-reported data to streamline workflows and support proactive interventions, achieving a 92% clinician satisfaction rate in European surveys. Peer-reviewed research linked to this symptom-monitoring approach shows up to a 38% reduction in hospitalizations, a 25% drop in severe treatment toxicities, and an average 1.9-month extension in treatment duration, outcomes that could translate into better resource utilization and revenue opportunities for U.S. providers.
Company leaders and advisors, including patient-reported outcomes expert Dr. Ethan Basch and Resilience Care’s Chief Medical and Patient Experience Officer Dr. Charles Ferté, emphasize that structured symptom capture enables earlier detection of complications and more effective clinical responses. Strategically, the U.S. launch positions Resilience Care to monetize its continuous cancer care model in a large, complex oncology market by helping health systems and practices improve outcomes, enhance nurse efficiency, and capture new reimbursement tied to proactive, data-driven remote care.